Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
Neurophotonics ; 11(3): 034310, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38881627

ABSTRACT

Significance: Widefield microscopy of the entire dorsal part of mouse cerebral cortex enables large-scale ("mesoscopic") imaging of different aspects of neuronal activity with spectrally compatible fluorescent indicators as well as hemodynamics via oxy- and deoxyhemoglobin absorption. Versatile and cost-effective imaging systems are needed for large-scale, color-multiplexed imaging of multiple fluorescent and intrinsic contrasts. Aim: We aim to develop a system for mesoscopic imaging of two fluorescent and two reflectance channels. Approach: Excitation of red and green fluorescence is achieved through epi-illumination. Hemoglobin absorption imaging is achieved using 525- and 625-nm light-emitting diodes positioned around the objective lens. An aluminum hemisphere placed between objective and cranial window provides diffuse illumination of the brain. Signals are recorded sequentially by a single sCMOS detector. Results: We demonstrate the performance of our imaging system by recording large-scale spontaneous and stimulus-evoked neuronal, cholinergic, and hemodynamic activity in awake, head-fixed mice with a curved "crystal skull" window expressing the red calcium indicator jRGECO1a and the green acetylcholine sensor GRAB ACh 3.0 . Shielding of illumination light through the aluminum hemisphere enables concurrent recording of pupil diameter changes. Conclusions: Our widefield microscope design with a single camera can be used to acquire multiple aspects of brain physiology and is compatible with behavioral readouts of pupil diameter.

2.
bioRxiv ; 2024 Mar 13.
Article in English | MEDLINE | ID: mdl-37986755

ABSTRACT

SIGNIFICANCE: Widefield microscopy of the entire dorsal part of mouse cerebral cortex enables large-scale (mesoscopic) imaging of neuronal activity with fluorescent indicators as well as hemodynamics via oxy- and deoxyhemoglobin absorption. Versatile and cost-effective imaging systems are needed for large-scale, color-multiplexed imaging of multiple fluorescent and intrinsic contrasts. AIM: Develop a system for mesoscopic imaging of two fluorescent and two reflectance channels. APPROACH: Excitation of red and green fluorescence is achieved through epi-illumination. Hemoglobin absorption imaging is achieved using 525- and 625nm LEDs positioned around the objective lens. An aluminum hemisphere placed between objective and cranial window provides diffuse illumination of the brain. Signals are recorded sequentially by a single sCMOS detector. RESULTS: We demonstrate performance of our imaging system by recording large-scale spontaneous and stimulus-evoked neuronal, cholinergic, and hemodynamic activity in awake head-fixed mice with a curved crystal skull window expressing the red calcium indicator jRGECO1a and the green acetylcholine sensor GRABACh3.0 . Shielding of illumination light through the aluminum hemisphere enables concurrent recording of pupil diameter changes. CONCLUSIONS: Our widefield microscope design with single camera can be used to acquire multiple aspects of brain physiology and is compatible with behavioral readouts of pupil diameter.

3.
iScience ; 24(9): 102955, 2021 Sep 24.
Article in English | MEDLINE | ID: mdl-34458703

ABSTRACT

Ultrasound modulates brain activity. However, it remains unclear how ultrasound affects individual neurons in the brain, where neural circuit architecture is intact and different brain regions exhibit distinct tissue properties. Using a high-resolution calcium imaging technique, we characterized the effect of ultrasound stimulation on thousands of individual neurons in the hippocampus and the motor cortex of awake mice. We found that brief 100-ms-long ultrasound pulses increase intracellular calcium in a large fraction of individual neurons in both brain regions. Ultrasound-evoked calcium response in hippocampal neurons exhibits a rapid onset with a latency shorter than 50 ms. The evoked response in the hippocampus is shorter in duration and smaller in magnitude than that in the motor cortex. These results demonstrate that noninvasive ultrasound stimulation transiently increases intracellular calcium in individual neurons in awake mice, and the evoked response profiles are brain region specific.

4.
Oncogene ; 27(19): 2746-53, 2008 Apr 24.
Article in English | MEDLINE | ID: mdl-17998935

ABSTRACT

Loss of the von Hippel-Lindau (VHL) tumor suppressor gene contributes to proliferative disorders including renal cell carcinoma. The consequence of VHL loss is increased levels of hypoxia-inducible factor-alpha (HIFalpha), which is targeted for proteolytic degradation by the VHL gene product pVHL. HIF is a transcription factor that increases the expression of factors critical for tumorigenesis in renal cell carcinoma. We report here another regulatory component of HIFalpha expression in renal cancer cells. Phospholipase D (PLD), which is commonly elevated in renal and other cancers, is required for elevated levels of both HIF1alpha and HIF2alpha in VHL-deficient renal cancer cells. The induction of both HIF1alpha and HIF2alpha by hypoxic mimetic conditions was also dependent on PLD in renal cancer cells with restored pVHL expression. The effect of PLD activity upon HIFalpha expression was at the level of translation. PLD activity also provides a survival signal that suppresses apoptosis induced by serum deprivation in the renal cancer cells. Suppression of HIF2alpha has been shown to reverse tumorigenesis with renal cancer cells. The finding here that HIF2alpha expression is dependent on PLD in renal cancer cells suggests that targeting PLD signals may represent an alternative therapeutic strategy for targeting HIF2alpha in renal cancers where HIF2alpha is critical for tumorigenesis and elevated PLD activity is common.


Subject(s)
Carcinoma, Renal Cell/metabolism , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Kidney Neoplasms/metabolism , Phospholipase D/physiology , Von Hippel-Lindau Tumor Suppressor Protein/genetics , Carcinoma, Renal Cell/enzymology , Cell Line, Tumor , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/biosynthesis , Kidney Neoplasms/enzymology , Protein Biosynthesis/physiology , von Hippel-Lindau Disease/genetics
5.
Percept Mot Skills ; 93(1): 47-50, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11693705

ABSTRACT

This study examined facial expression in the presentation of sarcasm. 60 responses (sarcastic responses = 30, nonsarcastic responses = 30) from 40 different speakers were coded by two trained coders. Expressions in three facial areas--eyebrow, eyes, and mouth--were evaluated. Only movement in the mouth area significantly differentiated ratings of sarcasm from nonsarcasm.


Subject(s)
Affect , Facial Expression , Eye , Humans , Mouth , Visual Perception/physiology
6.
Am Fam Physician ; 63(6): 1113-6, 2001 Mar 15.
Article in English | MEDLINE | ID: mdl-11277548

ABSTRACT

Paronychia is one of the most common infections of the hand. Clinically, paronychia presents as an acute or a chronic condition. It is a localized, superficial infection or abscess of the paronychial tissues of the hands or, less commonly, the feet. Any disruption of the seal between the proximal nail fold and the nail plate can cause acute infections of the eponychial space by providing a portal of entry for bacteria. Treatment options for acute paronychias include warm-water soaks, oral antibiotic therapy and surgical drainage. In cases of chronic paronychia, it is important that the patient avoid possible irritants. Treatment options include the use of topical antifungal agents and steroids, and surgical intervention. Patients with chronic paronychias that are unresponsive to therapy should be checked for unusual causes, such as malignancy.


Subject(s)
Paronychia , Abscess/etiology , Abscess/surgery , Acute Disease , Anti-Bacterial Agents/therapeutic use , Candidiasis/complications , Chronic Disease , Humans , Nails/anatomy & histology , Paronychia/diagnosis , Paronychia/etiology , Paronychia/therapy
7.
Laryngoscope ; 111(10): 1834-41, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11801954

ABSTRACT

OBJECTIVES: Vascular endothelial growth factor receptor 2 (VEGFR2; Flk-1 [fetal liver kinase]/KDR [kinase insert domain containing receptor]) has been identified as a high affinity receptor for vascular endothelial growth factor (VEGF) on vascular endothelium. Head and neck squamous cell carcinomas (HNSCC) have already been shown to produce substantial amounts of VEGF. VEGFR2 is supposed to play a major role in tumor-neoangiogenesis. METHODS: We investigated 24 tumor specimens and 4 HNSCC cultured tumor cell lines for the incidence and distribution of VEGFR2 by immunohistochemistry using monoclonal antibodies (mAbs) and RT-PCR. RESULTS: Analysis of frozen sections by immunohistochemistry showed that in 90% of tumor specimens VEGFR2-positive cells were found which were associated with vascular endothelium. VEGFR2 was also expressed on tumor cells and vessels, which was confirmed by double immunolabeling of tumor cells with an a-cytokeratin mAb. Furthermore, 2 (JPPA, SCC9) of 4 HNSCC cultured tumor cell lines revealed positive VEGFR2 immunoreactivity. Synthesis of VEGFR2 mRNA on all 4 HNSCC cultured tumor cell lines (JPPA, SCC9, SCC25, and LFFR) and in 6 tumor specimens was confirmed by RT-PCR. In conclusion, our results showed that VEGFR2 is expressed in HNSCCs on tumor cells. VEGFR2 expression is associated with the beginning of vasculogenesis represented by accumulation of VEGFR2-positive cells budding into new vessels ("hot spots"). The focal expression pattern of VEGFR2 on tumor cells suggests an autocrine loop for VEGF in tumor cell growth.


Subject(s)
Carcinoma, Squamous Cell/genetics , Otorhinolaryngologic Neoplasms/genetics , RNA, Messenger/genetics , Receptor Protein-Tyrosine Kinases/genetics , Receptors, Growth Factor/genetics , Adult , Aged , Carcinoma, Squamous Cell/blood supply , Carcinoma, Squamous Cell/pathology , Cell Division/physiology , Endothelial Growth Factors/metabolism , Female , Gene Expression Regulation, Neoplastic/physiology , Humans , Lymphokines/metabolism , Male , Middle Aged , Neoplasm Staging , Neovascularization, Pathologic/genetics , Neovascularization, Pathologic/pathology , Otorhinolaryngologic Neoplasms/blood supply , Otorhinolaryngologic Neoplasms/pathology , Receptors, Vascular Endothelial Growth Factor , Reverse Transcriptase Polymerase Chain Reaction , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
8.
Percept Mot Skills ; 91(2): 665-8, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11065329

ABSTRACT

This study compared actors', partners', and observers' perceptions of the amount of sarcasm used by participants (n = 80) in videotaped conversations. Significant differences were found among perceptions of actors, partners, and observers. Of the three perspectives, actors perceived themselves as using the greatest amount of sarcasm, followed by partners' perceptions of actors. Observers perceived actors as using the least amount of sarcasm. Correlations conducted to assess whether partners and observers recognized actors' individual attempts at sarcasm during the conversations were generally low.


Subject(s)
Affect , Interpersonal Relations , Social Perception , Verbal Behavior , Adult , Female , Humans , Male
9.
Mol Reprod Dev ; 55(3): 335-49, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10657053

ABSTRACT

The onset of the zona pellucida-induced acrosome reaction in mouse sperm is marked by loss of the pH gradient existing in acrosome-intact sperm between the acidic acrosomal lumen and the suspending medium, due to pore formation between outer acrosomal and plasma membranes. In earlier work, it was shown that this pH gradient loss occurred in single sperm bound to structurally intact zonae pellucidae with a half-time of 2.1 min; the extended kinetics of this loss determined in a sperm population bound to intact zonae was due to a 180-min range of variable lag times. We hypothesized that this lag time range was due to steric constraints imposed by the three-dimensional structure of the structurally intact zona pellucida, and that this constraint should be removed in solubilized zonae. The fluorescent probe, Dapoxyl(TM) (2-aminoethyl)sulfonamide (DAES) allowed a test of this hypothesis in a population of sperm cells. It is a weak base that is non-fluorescent in aqueous solution, but which accumulates in the acidic acrosomal compartment due to the pH gradient with highly enhanced fluorescence; loss of the pH gradient leads to a decrease in fluorescence. The half-time for DAES fluorescence loss in a population of capacitated, acrosome-intact sperm in response to solubilized zona pellucida protein was 2.13 +/- 0.10 min (SEM, n = 9). The agreement between single cell and cell population kinetics validates the hypothesis of steric constraint in the structurally intact zona pellucida. The change in intracellular Ca(2+) concentration in response to solubilized zona pellucida, as monitored with fluo-3, was a rapid increase, followed by a decrease, with a half-time of 0.85 +/- 0.09 min (SEM, n = 6) to a steady state level higher than the initial level, indicating this Ca(2+) transient as the precursor reaction to onset of the zona-induced acrosome reaction.


Subject(s)
Acrosome Reaction , Aniline Compounds/pharmacology , Calcium/metabolism , Receptors, Cell Surface , Xanthenes/pharmacology , Zona Pellucida/drug effects , Acrosome/metabolism , Animals , Dose-Response Relationship, Drug , Egg Proteins/metabolism , Female , Fluorescent Dyes/pharmacology , Fluorometry , Hydrogen-Ion Concentration , Ionomycin/pharmacology , Kinetics , Male , Membrane Glycoproteins/metabolism , Mice , Taurine/pharmacology , Time Factors , Zona Pellucida Glycoproteins
10.
Arch Biochem Biophys ; 374(2): 325-33, 2000 Feb 15.
Article in English | MEDLINE | ID: mdl-10666314

ABSTRACT

Inclusions containing ubiquitin-protein aggregates appear in neurons of patients with neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. The relationship between inclusion production and cell viability is not understood. To address this issue, we investigated the response of an established mouse neuronal cell line and of embryonic rat mesencephalic cultures to inhibition of the ubiquitin/proteasome pathway. Two proteasome inhibitors, a peptidyl aldehyde and an epoxy ketone, which cause accumulation of ubiquitinated proteins, were found to enhance expression of stress-inducible genes, including HSP70i and the polyubiquitin genes UbB and UbC. Under these conditions, mRNA and protein levels of the inducible form of cyclooxygenase (COX-2) were upregulated together with its product, PGE(2), a proinflammatory prostaglandin. Proteasomal inhibition also led to stabilization of COX-2 as ubiquitin conjugates, suggesting that the ubiquitin/proteasome pathway contributes to the regulation of COX-2 protein levels. Treatment with antioxidants known to inhibit NFkappaB and AP-1 transcriptional activation failed to abrogate COX-2 upregulation. Instead, these inhibitors exacerbated the stress response by potentiating HSP70i levels while eliciting a decrease in PGE(2) production. These findings suggest that the accumulation of ubiquitinated proteins resulting from proteasome inhibition in neuronal cells is associated with a proinflammatory response that may be an important contributor to neurodegeneration.


Subject(s)
Cysteine Endopeptidases/metabolism , Cysteine Proteinase Inhibitors/pharmacology , Dinoprostone/metabolism , Isoenzymes/genetics , Isoenzymes/metabolism , Multienzyme Complexes/metabolism , Neurons/physiology , Prostaglandin-Endoperoxide Synthases/genetics , Prostaglandin-Endoperoxide Synthases/metabolism , Ubiquitins/metabolism , Animals , Cell Differentiation , Cells, Cultured , Cyclooxygenase 1 , Cyclooxygenase 2 , Embryo, Mammalian , Enzyme Induction , Gene Expression Regulation, Enzymologic/drug effects , Inflammation , Kinetics , Membrane Proteins , Mesencephalon/cytology , Mesencephalon/physiology , Mice , Neuroblastoma , Neurons/drug effects , Neurons/enzymology , Proteasome Endopeptidase Complex , RNA, Messenger/genetics , Rats , Tumor Cells, Cultured
11.
Mol Reprod Dev ; 54(4): 418-28, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10542383

ABSTRACT

In order to calculate the actual, rather than the relative, intracellular Ca(2+) concentration (Ca(2+))(i) in mammalian sperm cells, using fluorescent probes whose fluorescence emission differs between the probe. Ca(2+) complex and free probe, the value of the dissociation constant for the probe. Ca(2+) complex, K(D), is required. Interaction of the probe with cellular components may change the intracellular value of K(D) from that determined in buffered solution. We had previously shown that fluo-3, whose Ca(2+) complex is highly fluorescent whereas free fluo-3 is not, could be used to monitor changes of (Ca(2+))(i) in mouse sperm. In this report, we describe a method for determining K(D) for the fluo-3. Ca(2+) complex in mouse sperm suspended in medium MJB, a medium in which the sperm remain viable, but which contains high Ca(2+). The method involved treating the sperm with ionomycin to provide a plasma membrane Ca(2+) carrier, with nigericin to eliminate pH gradient, and with gramicidin D to eliminate membrane potential, such that (Ca(2+))(i) equilibrates with medium Ca(2+) concentration (Ca(2+))(e), then titrating (Ca(2+))(e) with EGTA in added aliquots to near nil concentration. At EGTA concentrations in excess of total medium Ca(2+), an approximation algorithm was used to calculate (Ca(2+))(e), based on the known K(D) for the EGTA. Ca(2+) complex. The fluorescence of the intracellular fluo-3. Ca(2+) complex, F, decreased with increasing additions of EGTA; (Ca(2+))(i) = (Ca(2+))(e) was plotted as a linear function of F/[F(max) - F]; the slope gives K(D). At 37 degrees C, intracellular K(D) was calculated to be 0.636 +/- 0.018 microM (+/-SEM, n = 8). At 37 degrees C and 20 degrees C, K(D) values in MJB were calculated to be 0.502 +/- 0.022 and 0.578 +/- 0.029 (+/-SEM, n =8 and n = 6), respectively. The higher intracellular K(D) value implies probe interaction with cytosol components, primarily those in the head, as this compartment is the major contributor to sperm fluorescence. Changes in (Ca(2+))(i), monitored with fluo-3 fluorescence, that occur on interaction of capacitated mouse sperm with the zona pellucida and may now be quantified, using 0.636 microM for K(D) of the intracellular fluo-3. Ca(2+) complex.


Subject(s)
Aniline Compounds/metabolism , Calcium/metabolism , Spermatozoa/metabolism , Xanthenes/metabolism , Animals , Cells, Cultured , Culture Media/chemistry , Egtazic Acid/metabolism , Kinetics , Male , Mice , Models, Chemical , Octoxynol/analysis , Spectrometry, Fluorescence
12.
Cancer Metastasis Rev ; 17(2): 155-61, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9770111

ABSTRACT

Biological evidence suggests that interference with the function of the angiogenic growth factor receptor VEGFR2 (flk1/KDR) is a particularly promising strategy to inhibit tumor-induced angiogenesis. Proof of concept was established by developing a monoclonal rat anti-mouse VEGFR2 antibody (DC101) and showing that it potently blocked the binding of VEGF to its receptor, inhibited VEGF-induced signaling, and strongly blocked tumor growth in mice through an anti-angiogenic mechanism. Since DC101 does not cross-react with the human VEGFR2 KDR, anti-KDR monoclonal antibodies were generated by standard hybridoma technology and by using phage display library. High affinity antibodies (Kd = 4.9 x 10(-10)-1.1 x 10(-9) M) were found with both approaches. The anti-KDR antibodies compete on an equimolar basis with VEGF for binding to KDR and inhibit with similar potency the VEGF-induced signaling and mitogenesis in human endothelial cells. Although these antibodies cannot be tested for in vivo efficacy in standard murine tumor models because of lack of species cross-reactivity, the similarity of their in vitro properties with those of DC101 suggests that they may be effective in blocking KDR function in vivo.


Subject(s)
Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/therapeutic use , Neoplasms/blood supply , Neoplasms/drug therapy , Neovascularization, Pathologic/prevention & control , Receptor Protein-Tyrosine Kinases/immunology , Receptors, Growth Factor/immunology , Animals , Humans , Mice , Neoplasms, Experimental/blood supply , Neoplasms, Experimental/drug therapy , Neovascularization, Pathologic/immunology , Rats , Receptors, Mitogen/immunology , Receptors, Vascular Endothelial Growth Factor , Signal Transduction/drug effects
13.
Cancer Res ; 58(15): 3209-14, 1998 Aug 01.
Article in English | MEDLINE | ID: mdl-9699643

ABSTRACT

A single-chain antibody phage display library was constructed from spleen cells of mice immunized with a soluble form of a human vascular endothelial growth factor (VEGF) receptor, kinase insert domain-containing receptor (KDR). After two rounds of biopanning, >90% of the clones recovered were specifically reactive to KDR. Subsequent selection identified two clones that blocked VEGF binding to KDR. The clones were expressed in Escherichia coli and purified as soluble single-chain Fv (scFv) antibodies. The affinities of the scFv for binding to KDR were determined by BIAcore analysis (2.1 x 10(-9)-5.9 x 10(-9) M). One scFv, p1C11, was shown to inhibit VEGF-induced KDR phosphorylation and VEGF-stimulated DNA synthesis in human umbilical vein endothelial cells. There is much experimental evidence to suggest that the VEGF/KDR/Flk-1 pathway plays an important role in tumor angiogenesis, a process that is essential for tumor growth and metastasis. The antibodies discussed here, which block VEGF binding to KDR, have potential clinical application in the treatment of cancer and other diseases where pathological angiogenesis is involved.


Subject(s)
Endothelial Growth Factors/antagonists & inhibitors , Immunoglobulin Fragments/pharmacology , Lymphokines/antagonists & inhibitors , Receptor Protein-Tyrosine Kinases/immunology , Receptors, Growth Factor/immunology , 3T3 Cells , Amino Acid Sequence , Animals , Bacteriophages/genetics , Cells, Cultured , DNA/biosynthesis , Endothelial Growth Factors/metabolism , Endothelial Growth Factors/pharmacology , Endothelium, Vascular/metabolism , Escherichia coli/genetics , Escherichia coli/metabolism , Female , Humans , Immunoglobulin Fragments/biosynthesis , Immunoglobulin Fragments/genetics , Lymphokines/metabolism , Lymphokines/pharmacology , Male , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Phosphorylation , Protein Structure, Tertiary , RNA, Messenger/metabolism , Receptor Protein-Tyrosine Kinases/drug effects , Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Growth Factor/drug effects , Receptors, Growth Factor/metabolism , Receptors, Vascular Endothelial Growth Factor , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
14.
Am J Pathol ; 151(6): 1523-30, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9403702

ABSTRACT

The overexpression in tumor cells of (proto)-oncogenic receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) or ErbB2/neu (also known as HER-2) is generally thought to contribute to the development of solid tumors primarily through their effects on promoting uncontrolled cell proliferation. However, agents that antagonize the function of the protein products encoded by these (proto)-oncogenes are known to behave in vivo in a cytotoxic-like manner. This implies that such oncogenes may regulate critical cell survival functions, including angiogenesis. The latter could occur as a consequence of regulation of relevant growth factors by such oncogenes. We therefore sought to determine whether EGFR or ErbB2/neu may contribute to tumor angiogenesis by examining their effects on the expression of vascular endothelial cell growth factor (VEGF)/vascular permeability factor (VPF), one of the most important of all known inducers of tumor angiogenesis. We found that in vitro treatment of EGFR-positive A431 human epidermoid carcinoma cells, which are known to be heavily dependent on VEGF/VPF in vivo as an angiogenesis growth factor, with the C225 anti-EGFR neutralizing antibody caused a dose-dependent inhibition of VEGF protein expression. Prominent suppression of VEGF/VPF expression in vivo, as well as a significant reduction in tumor blood vessel counts, were also observed in established A431 tumors shortly after injection of the antibody as few as four times into nude mice. Transformation of NIH 3T3 fibroblasts with mutant ErbB2/neu, another EGFR-like oncogenic tyrosine kinase, resulted in a significant induction of VEGF/VPF, and the magnitude of this effect was further elevated by hypoxia. Moreover, treatment of ErbB2/neu-positive SKBR-3 human breast cancer cells in vitro with a specific neutralizing anti-ErbB2/neu monoclonal antibody (4D5) resulted in a dose-dependent reduction of VEGF/VPF protein expression. Taken together, the results suggest that oncogenic properties of EGFR and ErbB2/neu may, at least in part, be mediated by stimulation of tumor angiogenesis by up-regulating potent angiogenesis growth factors such as VEGF/VPF. These genetic changes may cooperate with epigenetic/environmental effects such as hypoxia to maximally stimulate VEGF/VPF expression. Therapeutic disruption of EGFR or ErbB2/neu protein function in vivo may therefore result in partial suppression of angiogenesis, a feature that could enhance the therapeutic index of such agents in vivo and endow them with anti-tumor effects, the magnitude of which may be out of proportion with their observed cytostatic effects in monolayer tissue culture.


Subject(s)
Adenocarcinoma/metabolism , Antibodies, Monoclonal/pharmacology , Breast Neoplasms/metabolism , Carcinoma, Squamous Cell/metabolism , Endothelial Growth Factors/metabolism , Epidermal Growth Factor/immunology , Lymphokines/metabolism , Neovascularization, Pathologic/metabolism , Receptor, ErbB-2/immunology , Signal Transduction/physiology , Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Animals , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/pathology , Dose-Response Relationship, Drug , Down-Regulation/drug effects , Gene Expression Regulation, Neoplastic , Humans , Immunoenzyme Techniques , Mice , Mice, Nude , Neoplasm Transplantation , Neovascularization, Pathologic/drug therapy , Neovascularization, Pathologic/pathology , Neutralization Tests , Tumor Cells, Cultured , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
15.
Nat Med ; 3(11): 1222-7, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9359696

ABSTRACT

The importance of angiogenesis in malignant tumor growth has been interpreted mainly in terms of oxygen and nutrient supply. Here we demonstrate its fundamental role for tumor invasion of malignant human keratinocytes in surface transplants on nude mice. Distinct patterns of angiogenesis and vascular endothelial growth factor receptor-2 (VEGFR-2) expression allowed us to distinguish between benign and malignant cells. Functional inactivation of VEGF-R2 by a blocking antibody disrupted ongoing angiogenesis and prevented invasion of malignant cells, without reducing tumor cell proliferation. The reversion of a malignant into a benign phenotype by halting angiogenesis demonstrates a significant function of vascular endothelium for tumor invasion.


Subject(s)
Neoplasm Invasiveness , Neovascularization, Pathologic/complications , Animals , Cell Transformation, Neoplastic , Endothelial Growth Factors/biosynthesis , Fluorescent Antibody Technique, Indirect , Humans , In Situ Hybridization , Lymphokines/biosynthesis , Mice , Mice, Nude , Neoplasm Transplantation , Receptor Protein-Tyrosine Kinases/biosynthesis , Receptors, Growth Factor/biosynthesis , Receptors, Mitogen/biosynthesis , Receptors, Vascular Endothelial Growth Factor , Transfection , Tumor Cells, Cultured , Up-Regulation , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
16.
Proc Natl Acad Sci U S A ; 94(12): 6523-8, 1997 Jun 10.
Article in English | MEDLINE | ID: mdl-9177251

ABSTRACT

Antisense oligodeoxynucleotides offer potential as therapeutic agents to inhibit gene expression. Recent evidence indicates that oligodeoxynucleotides designed to target specific nucleic acid sequences can interact nonspecifically with proteins. This report describes the interactive capabilities of phosphorothioate oligodeoxynucleotides of defined sequence and length with two essential protein tyrosine receptors, flk-1 and epidermal growth factor receptor (EGFR), and their effects on receptor signaling in a transfected and tumor cell line, respectively. Phosphorothioate oligodeoxynucleotides bound to the cell surface, as demonstrated by fluorescence-activated cell-sorter analyses (FACS), and perturbed receptor activation in the presence and absence of cognate ligands, EGF (EGFR) and vascular endothelial growth factor (flk-1), in phosphorylation assays. Certain phosphorothioate oligodeoxynucleotides interacted relatively selectively with flk-1 and partially blocked the binding of specific anti-receptor monoclonal antibodies to target sites. They stimulated EGFR phosphorylation in the absence of EGF but antagonized ligand-mediated activation of EGFR and flk-1. In vivo studies showed that a nonspecific phosphorothioate oligodeoxynucleotide suppressed the growth of glioblastoma in a mouse model of tumorigenesis. These results emphasize the capacity of phosphorothioate oligodeoxynucleotides to interact with cells in a sequence-selective nonantisense manner, while associating with cellular membrane proteins in ways that can inhibit cellular metabolic activities.


Subject(s)
Antineoplastic Agents/pharmacology , Cell Membrane/physiology , Endothelial Growth Factors/pharmacology , Epidermal Growth Factor/pharmacology , ErbB Receptors/drug effects , Glioblastoma/pathology , Lymphokines/pharmacology , Oligonucleotides, Antisense/pharmacology , Receptor Protein-Tyrosine Kinases/drug effects , Receptors, Growth Factor/drug effects , 3T3 Cells , Animals , Base Sequence , Cell Membrane/drug effects , ErbB Receptors/physiology , Glioblastoma/drug therapy , Humans , KB Cells , Mice , Mice, Nude , Phosphorylation , Receptor Protein-Tyrosine Kinases/physiology , Receptors, Growth Factor/physiology , Receptors, Vascular Endothelial Growth Factor , Thionucleotides , Transplantation, Heterologous , Tumor Cells, Cultured , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
17.
J Immunother Emphasis Tumor Immunol ; 19(6): 419-27, 1996 Nov.
Article in English | MEDLINE | ID: mdl-9041461

ABSTRACT

For prostate cancer, a correlation exists between overexpression of the epidermal growth factor receptor (EGFR) and poor clinical prognosis. In addition, late-stage metastatic disease is characterized by a change from a paracrine to an autocrine mode of expression for TGF-alpha, the ligand for the EGFR. These observations suggest that activation of the EGFR may be important for the growth of prostatic carcinoma in situ, and blockade of the receptor-ligand interaction may offer a means of therapeutic intervention for this disease. We describe the biologic effects of a chimeric anti-EGFR monoclonal antibody, C225, on several human prostate tumor cell lines in culture and the tumor inhibitory properties of the antibody for the treatment of human prostate carcinoma xenografts in nude mice. In vitro analysis of the EGFR from androgen-responsive and independent prostatic carcinoma cell lines revealed that C225 blocked EGF-induced receptor activation and induced internalization of the receptor. In vivo, a treatment regimen of C225 alone or antibody plus doxorubicin significantly inhibited tumor progression of well-established DU145 and PC-3 xenografts in nude mice. These results suggest that C225 may have utility for the treatment of human prostate carcinoma in a clinical setting.


Subject(s)
Antibodies, Monoclonal/pharmacology , Carcinoma/immunology , ErbB Receptors/immunology , Prostatic Neoplasms/immunology , Recombinant Fusion Proteins/immunology , Animals , Antibodies, Blocking/pharmacology , Antibodies, Monoclonal, Humanized , Carcinoma/metabolism , Carcinoma/therapy , Cetuximab , ErbB Receptors/antagonists & inhibitors , Humans , Immunization, Passive , Male , Mice , Mice, Nude , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/therapy , Recombinant Fusion Proteins/pharmacology , Tumor Cells, Cultured
18.
Percept Mot Skills ; 82(3 Pt 2): 1241-2, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8823889

ABSTRACT

Participants (N = 139) listened to 15 speakers (8 deceptive, 7 truthful) in one of three conditions, left ear (right hemisphere), right ear (left hemisphere), and both ears (combined hemispheres) and attempted to decide which speakers were deceptive. Accuracy of detection was not significantly different across the three conditions.


Subject(s)
Deception , Dominance, Cerebral , Speech Perception , Attention , Humans
19.
J Psycholinguist Res ; 25(3): 431-41, 1996 May.
Article in English | MEDLINE | ID: mdl-8648593

ABSTRACT

The effects of variations in speaker rate and pitch on listener recall were studied. One hundred and twenty participants listened to an audiotape of one of two individuals speaking in one of four different styles--low variation in both rate and pitch, variation in rate but not in pitch, variation in pitch but not in rate, and variation in both rate and pitch. After hearing the audiotape, listeners were tested on the information in the presentation; they also completed questionnaires rating the speaker's benevolence and competence. Results indicated that the combined effect of pitch and rate variety significantly increased listener recall over no variety or pitch variety increased attributions of speaker competence over no variety or rate variety or rate variety alone. Additionally, pitch variety and combined pitch and rate variety significantly increased attributions of speaker competence over no variety or rate variety alone, but significantly decreased attributions of speaker benevolence.


Subject(s)
Mental Recall , Speech Perception , Speech , Voice , Adult , Female , Humans , Male , Pitch Perception , Surveys and Questionnaires , Voice Quality
20.
J Biol Chem ; 271(10): 5519-23, 1996 Mar 08.
Article in English | MEDLINE | ID: mdl-8621410

ABSTRACT

VEGF121 and VEGF165 are vascular endothelial growth factor splice variants that promote the proliferation of endothelial cells and angiogenesis. VEGF165 contains the 44 additional amino acids encoded by exon 7 of the VEGF gene. These amino acids confer upon VEGF165 a heparin binding capability which VEGF121 lacks. 125I-VEGF165 bound to three vascular endothelial growth factor (VEGF) receptors on endothelial cells, while 125I-VEGF121 bound selectively only to the flk-1 VEGF receptor which corresponds to the larger of the three VEGF receptors. The binding of 125I-VEGF121 to flk-1 was not affected by the removal of cell surface heparan sulfates or by heparin. Both VEGF165 and VEGF121 inhibited the binding of 125I-VEGF121 to a soluble extracellular domain of the flk-1 VEGF receptor in the absence of heparin. However, heparin potentiated the inhibitory effect of VEGF165 by 2-3-fold. These results contrast with previous observations which have indicated that the binding of 125I-VEGF165 to the flk-1 receptor is strongly dependent on heparin-like molecules. Further experiments showed that the receptor binding ability of VEGF165 is susceptible to oxidative damage caused by oxidants such as H2O2 or chloramine-T. VEGF121 was also damaged by oxidants but to a lesser extent. Heparin or cell surface heparan sulfates restored the flk-1 binding ability of damaged VEGF165 but not the receptor binding ability of damaged VEGF121. These observations suggest that alternative splicing can generate a diversity in growth factor signaling by determining receptor recognition patterns. They also indicate that the heparin binding ability of VEGF165 may enable the restoration of damaged VEGF165 function in processes such as inflammation or wound healing.


Subject(s)
Endothelial Growth Factors/metabolism , Endothelial Growth Factors/pharmacology , Endothelium, Vascular/metabolism , Lymphokines/metabolism , Lymphokines/pharmacology , Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Growth Factor/metabolism , Animals , Binding, Competitive , Cell Line , Cells, Cultured , Chloramines/pharmacology , Electrophoresis, Polyacrylamide Gel , Endothelial Growth Factors/isolation & purification , Genetic Variation , Heparin/pharmacology , Heparitin Sulfate/pharmacology , Humans , Kinetics , Lymphokines/isolation & purification , Molecular Weight , Oxidants/pharmacology , Oxidation-Reduction , Receptor Protein-Tyrosine Kinases/isolation & purification , Receptors, Growth Factor/isolation & purification , Receptors, Vascular Endothelial Growth Factor , Recombinant Proteins/metabolism , Signal Transduction , Structure-Activity Relationship , Tosyl Compounds/pharmacology , Transfection , Umbilical Veins , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...